AR058982A1 - Vector de expresion de la proteina bicunina y metodo para producir dicha proteina - Google Patents
Vector de expresion de la proteina bicunina y metodo para producir dicha proteinaInfo
- Publication number
- AR058982A1 AR058982A1 ARP070100116A ARP070100116A AR058982A1 AR 058982 A1 AR058982 A1 AR 058982A1 AR P070100116 A ARP070100116 A AR P070100116A AR P070100116 A ARP070100116 A AR P070100116A AR 058982 A1 AR058982 A1 AR 058982A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- cysteine
- bicunin
- produce
- expression vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physics & Mathematics (AREA)
Abstract
Métodos tanto para producir la proteína como para inhibir la actividad de serina proteasa. Reivindicacion 1: Un vector autoreplicante de expresion de proteína caracterizado porque contiene una secuencia de ácido nucleico que codifica para y es capaz de expresar proteínas seleccionadas de al menos una de las siguientes secuencias proteicas. (Ver dibujo)à, donde los aminoácidos de las secuencias están numerados de acuerdo con la secuencia de aminoácidos de la bicunina placentaria humana mostrada en la SEC.ID. N°49; o donde dicha proteína está glicosilada, o contiene al menos un enlace de disulfuro cisteína-cisteína dentro de la cadena, o está glicosilada y también contiene al menos un enlace de disulfuro cisteína-cisteína dentro de la cadena; y un vehículo farmacéuticamente aceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1310696P | 1996-03-11 | 1996-03-11 | |
US1979396P | 1996-06-14 | 1996-06-14 | |
US72525196A | 1996-10-04 | 1996-10-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR058982A1 true AR058982A1 (es) | 2008-03-05 |
Family
ID=27359773
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100967A AR006188A1 (es) | 1996-03-11 | 1997-03-11 | "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". |
ARP060101562A AR053063A2 (es) | 1996-03-11 | 2006-04-20 | Proteina sustancialmente purificada y composicion farmaceutica que la comprende |
ARP070100116A AR058982A1 (es) | 1996-03-11 | 2007-01-11 | Vector de expresion de la proteina bicunina y metodo para producir dicha proteina |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100967A AR006188A1 (es) | 1996-03-11 | 1997-03-11 | "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion". |
ARP060101562A AR053063A2 (es) | 1996-03-11 | 2006-04-20 | Proteina sustancialmente purificada y composicion farmaceutica que la comprende |
Country Status (27)
Country | Link |
---|---|
US (3) | US6583108B1 (es) |
EP (1) | EP0891426B1 (es) |
JP (2) | JP3469584B2 (es) |
KR (1) | KR100356956B1 (es) |
AR (3) | AR006188A1 (es) |
AT (1) | ATE328083T1 (es) |
AU (1) | AU716923B2 (es) |
BR (1) | BR9708021A (es) |
CA (1) | CA2247888A1 (es) |
CO (1) | CO4600683A1 (es) |
DE (1) | DE69735996T2 (es) |
DK (1) | DK0891426T3 (es) |
ES (1) | ES2263174T3 (es) |
HR (1) | HRP970144B1 (es) |
HU (1) | HU226419B1 (es) |
ID (1) | ID16224A (es) |
IL (1) | IL126115A (es) |
IN (1) | IN192874B (es) |
MY (1) | MY120693A (es) |
NZ (1) | NZ331540A (es) |
PA (1) | PA8426301A1 (es) |
PL (1) | PL188387B1 (es) |
PT (1) | PT891426E (es) |
SV (1) | SV1997000018A (es) |
TR (1) | TR199801794T2 (es) |
WO (1) | WO1997033996A2 (es) |
YU (1) | YU8997A (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
EP0758682B1 (en) * | 1995-07-24 | 2004-05-12 | Mitsubishi Chemical Corporation | Hepatocyte growth factor activator inhibitor |
NZ331540A (en) | 1996-03-11 | 1999-10-28 | Bayer Ag | Human bikunin |
CA2279345A1 (en) * | 1997-01-31 | 1998-08-06 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
EP1374891B1 (en) * | 1998-12-22 | 2008-09-10 | Bayer Aktiengesellschaft | Method for accelerating the rate of mucociliary clearance |
US7704958B1 (en) | 1999-03-05 | 2010-04-27 | Bio Holding, Inc. | Methods and compositions for inhibiting apoptosis using serine protease inhibitors |
AU3511500A (en) | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
US20040235715A1 (en) * | 1999-11-12 | 2004-11-25 | Bayer Corporation | Method of producing glycosylated bikunin |
IL140994A (en) * | 2000-05-15 | 2005-12-18 | Bayer Ag | Urinary trypsin inhibitor assay containing a chelating agent |
IL140993A0 (en) | 2000-05-15 | 2002-02-10 | Bayer Ag | Trypsin substrate and diagnostic device, and method of using same |
US6955921B2 (en) * | 2001-04-30 | 2005-10-18 | Bayer Corporation | Trypsin substrate and diagnostic device, and method of using same |
WO2003040330A2 (en) * | 2001-11-05 | 2003-05-15 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
ATE512674T1 (de) | 2003-01-06 | 2011-07-15 | Angiochem Inc | Angiopep-1, verwandte verbindungen, und deren verwnedungen |
US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
US7244616B2 (en) | 2003-06-27 | 2007-07-17 | Bayer Pharmaceuticals Corporation | Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells |
US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
EP3192872A1 (en) | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
EP1704227B1 (en) * | 2003-10-10 | 2010-01-27 | Multicell Technologies, Inc. | Immortalized hepatocytes |
US7419665B2 (en) * | 2003-10-16 | 2008-09-02 | Siemens Healthcare Diagnostics Inc. | Monoclonal antibodies for detection of urinary trypsin inhibitors |
EP1586587A1 (en) * | 2004-04-16 | 2005-10-19 | Exonhit Therapeutics SA | Compositions and methods for detecting angiogenesis |
CA2858901C (en) | 2004-06-04 | 2024-01-16 | Carolyn Anderson | Diabetes care host-client architecture and data management system |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
ES2383901T5 (es) * | 2005-02-18 | 2015-02-25 | Angiochem Inc. | Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro |
US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
WO2007011693A2 (en) * | 2005-07-14 | 2007-01-25 | Medistem Laboratories, Inc. | Compositions of placentally-derived stem cells for the treatment of cancer |
EP2233156B1 (en) | 2005-07-15 | 2013-05-01 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
US8093017B2 (en) | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
EP1981519B1 (en) | 2005-12-29 | 2017-12-27 | Dyax Corp. | Protease inhibition |
CA2663545A1 (en) * | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
WO2008058167A2 (en) * | 2006-11-07 | 2008-05-15 | Case Western Reserve University | Method for treating disorders associated with complement activation |
WO2008077478A1 (en) * | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8822409B2 (en) * | 2007-06-20 | 2014-09-02 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith |
CA2696208A1 (en) * | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
DE102007056231A1 (de) | 2007-09-08 | 2009-03-12 | Bayer Healthcare Ag | Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI) |
ES2721148T3 (es) * | 2008-04-18 | 2019-07-29 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso |
BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
CN102245636A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | 用于药物递送的依托泊苷和多柔比星结合物 |
AU2009322043A1 (en) | 2008-12-05 | 2011-07-07 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
EP2421562B1 (en) | 2009-04-20 | 2019-03-13 | Angiochem Inc. | Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog |
CN102596993A (zh) | 2009-07-02 | 2012-07-18 | 安吉奥开米公司 | 多聚体肽结合物以及其应用 |
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
EP2371857A1 (en) * | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
BR112013017080A8 (pt) | 2011-01-06 | 2023-05-09 | Dyax Corp | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
US9938353B2 (en) | 2011-06-24 | 2018-04-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
CA2896951A1 (en) | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
CA2881602A1 (en) | 2012-08-14 | 2014-02-20 | Angiochem Inc. | Peptide-dendrimer conjugates and uses thereof |
JP6574431B2 (ja) | 2014-02-24 | 2019-09-11 | タケダ ゲー・エム・ベー・ハーTakeda GmbH | Uti融合タンパク質 |
US10428158B2 (en) | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
CA2989400A1 (en) | 2015-06-15 | 2016-12-22 | Angiochem Inc. | Ang1005 for the treatment of leptomeningeal carcinomatosis |
BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
US11725043B2 (en) | 2020-03-05 | 2023-08-15 | DiaMedica USA Inc. | Ulinastatin polypeptides |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223482A (en) | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
US5106833A (en) | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DK0401508T3 (da) | 1989-05-13 | 1995-05-15 | Bayer Ag | Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf |
DK408089D0 (da) | 1989-08-18 | 1989-08-18 | Novo Nordisk As | Proteiner |
EP0439442B1 (en) | 1990-01-25 | 1996-03-06 | Washington University | Factor x-laci hybrid protein |
ATE243710T1 (de) | 1991-03-01 | 2003-07-15 | Dyax Corp | Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g |
RU2054180C1 (ru) | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
IL104326A0 (en) | 1992-01-07 | 1993-05-13 | Novo Nordisk As | Variant of human kunitz-type protease inhibitor |
IL104325A (en) | 1992-01-07 | 2000-10-31 | Novo Nordisk As | Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above |
JPH07509229A (ja) | 1992-07-13 | 1995-10-12 | コルバス・インターナショナル、インコーポレイテッド | ウシ膵トリプシン阻害因子から誘導される因子Xaの阻害因子 |
US5436153A (en) | 1992-12-02 | 1995-07-25 | Sprecher; Cindy A. | Human amyloid protein precursor homolog and Kunitz-type inhibitor |
EP0740702A1 (en) | 1992-12-02 | 1996-11-06 | Zymogenetics, Inc. | Novel human amyloid protein precursor homologue and kunitz-type inhibitors |
JP2769083B2 (ja) | 1993-02-22 | 1998-06-25 | 日清食品株式会社 | エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法 |
US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
US5795865A (en) | 1994-01-11 | 1998-08-18 | Dyax Corp. | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
ATE529444T1 (de) | 1994-01-11 | 2011-11-15 | Dyax Corp | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten |
US5795954A (en) | 1994-03-04 | 1998-08-18 | Genentech, Inc. | Factor VIIa inhibitors from Kunitz domain proteins |
WO1996003503A1 (fr) | 1994-07-21 | 1996-02-08 | The Green Cross Corporation | Procede de production d'un inhibiteur de la trypsine urinaire et des domaines de celui-ci, nouveau polypeptide associe et procede de production de ce polypeptide |
US5541228A (en) * | 1994-10-14 | 1996-07-30 | Bristol-Myers Squibb Co. | Melatonergic agents |
EP0827539A2 (en) | 1995-05-08 | 1998-03-11 | Scios Inc. | Kunitz type protease inhibitors |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
EP0758682B1 (en) * | 1995-07-24 | 2004-05-12 | Mitsubishi Chemical Corporation | Hepatocyte growth factor activator inhibitor |
US5736364A (en) | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
NZ331540A (en) | 1996-03-11 | 1999-10-28 | Bayer Ag | Human bikunin |
CA2279345A1 (en) | 1997-01-31 | 1998-08-06 | Human Genome Sciences, Inc. | Tissue factor pathway inhibitor-3 |
US6294648B1 (en) * | 1999-07-20 | 2001-09-25 | Bayer Corporation | Protein having proteinase inhibitor activity |
-
1997
- 1997-03-10 NZ NZ331540A patent/NZ331540A/en unknown
- 1997-03-10 KR KR10-1998-0707163A patent/KR100356956B1/ko not_active IP Right Cessation
- 1997-03-10 TR TR1998/01794T patent/TR199801794T2/xx unknown
- 1997-03-10 CA CA002247888A patent/CA2247888A1/en not_active Abandoned
- 1997-03-10 HU HU9902698A patent/HU226419B1/hu not_active IP Right Cessation
- 1997-03-10 PL PL97328822A patent/PL188387B1/pl not_active IP Right Cessation
- 1997-03-10 WO PCT/US1997/003894 patent/WO1997033996A2/en active IP Right Grant
- 1997-03-10 AT AT97915029T patent/ATE328083T1/de not_active IP Right Cessation
- 1997-03-10 EP EP97915029A patent/EP0891426B1/en not_active Expired - Lifetime
- 1997-03-10 IL IL126115A patent/IL126115A/en not_active IP Right Cessation
- 1997-03-10 YU YU8997A patent/YU8997A/sh unknown
- 1997-03-10 ES ES97915029T patent/ES2263174T3/es not_active Expired - Lifetime
- 1997-03-10 JP JP53280497A patent/JP3469584B2/ja not_active Expired - Fee Related
- 1997-03-10 BR BR9708021A patent/BR9708021A/pt not_active Application Discontinuation
- 1997-03-10 DE DE69735996T patent/DE69735996T2/de not_active Expired - Fee Related
- 1997-03-10 PT PT97915029T patent/PT891426E/pt unknown
- 1997-03-10 DK DK97915029T patent/DK0891426T3/da active
- 1997-03-10 AU AU22077/97A patent/AU716923B2/en not_active Ceased
- 1997-03-11 MY MYPI97001015A patent/MY120693A/en unknown
- 1997-03-11 CO CO97013175A patent/CO4600683A1/es unknown
- 1997-03-11 HR HR970144A patent/HRP970144B1/xx not_active IP Right Cessation
- 1997-03-11 ID IDP970779A patent/ID16224A/id unknown
- 1997-03-11 IN IN601DE1997 patent/IN192874B/en unknown
- 1997-03-11 PA PA19978426301A patent/PA8426301A1/es unknown
- 1997-03-11 SV SV1997000018A patent/SV1997000018A/es not_active Application Discontinuation
- 1997-03-11 AR ARP970100967A patent/AR006188A1/es active IP Right Grant
-
1998
- 1998-08-31 US US09/144,428 patent/US6583108B1/en not_active Expired - Fee Related
-
2001
- 2001-10-10 US US09/974,026 patent/US7019123B2/en not_active Expired - Fee Related
-
2003
- 2003-04-23 JP JP2003119118A patent/JP2004000208A/ja active Pending
-
2006
- 2006-03-27 US US11/390,775 patent/US7452859B2/en not_active Expired - Fee Related
- 2006-04-20 AR ARP060101562A patent/AR053063A2/es unknown
-
2007
- 2007-01-11 AR ARP070100116A patent/AR058982A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR058982A1 (es) | Vector de expresion de la proteina bicunina y metodo para producir dicha proteina | |
Töpfer-Petersen et al. | Acrosin shows zona and fucose binding, novel properties for a serine proteinase | |
ES2124685T3 (es) | Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso. | |
AR009436A1 (es) | UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS. | |
RU95115239A (ru) | Аналог эритропоэтина | |
WO1998020133A3 (en) | Proteins with enhanced levels of essential amino acids | |
NO177678C (no) | Fremgangsmåte for fremstilling av et terapeutisk aktivt, rekombinant protein som har ASP-aktivitet, ekspresjonssystem samt DNA som koder for nevnte protein | |
DE68929043T2 (de) | Für androgen-rezeptor-protein kodierende dna | |
PT81991B (pt) | Processo para a preparacao de derivados peptidicos, analogos a pepestatina, inibidores darenina e das proteases acidas | |
MX9203519A (es) | Metodo de recombinacion para la produccion de inhibidores de proteasa de serina y secuencias de adn utiles para los mismos. | |
ES550943A0 (es) | Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana. | |
ES2140390T3 (es) | Metodos para la trans-desestabilizacion de proteinas in vivo. | |
ES2187782T3 (es) | Procedimiento para la produccion de polipeptidos. | |
NO885013D0 (no) | Fremgangsmte for fremstilling av bionedbrytbare mikrokapsler av vannopplelige peptider og proteiner, samt mikroka psler oppndd ved fremgangsmten. | |
DE69032258D1 (de) | Antikoagulierende Peptide | |
FR2766190B1 (fr) | Nouveaux peptides et polypeptides utiles dans la regeneration du systeme nerveux | |
PT90739A (pt) | Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina | |
EP0238473A3 (en) | Serine protease inhibitors | |
ATE177432T1 (de) | Antikoagulierende peptide | |
UA27997C2 (uk) | Агент екстракції периплазматичного рекомбінантного білка, спосіб одержання периплазматичного рекомбінантного білка (варіанти), спосіб культивування прокаріотичного мікроорганізму | |
PE20001068A1 (es) | Produccion de analogos de tripsinogeno recombinante solubles | |
TH62241A (th) | ไบคูนินของคน | |
DE3888078D1 (de) | Veränderungsverfahren für Peptide und Proteine. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |